Postponed: New target date Q4 2018 [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-02-15 13:04 (2315 d 02:24 ago) – Posting: # 18421
Views: 4,608

Dear all,

Guideline on the investigation of bioequivalence (Appendix 1)
Target date

Q4 2018 (+ one year)


This is a joint request from the CHMP Pharmacokinetics WP and the Quality WP. Following the publication of the Reflection Paper on statistical methodology for the comparative assessment of quality attributes in drug development, finalise the discussion with PKWP and QWP on the acceptability of the Mahalanobis distance for the similarity of dissolution profiles. The final output may be included in the aforementioned Reflection Paper or may form a Q&A.

Type I error control in two-stage designs in bioequivalence studies
Target date

Q4 2018 (+ 1½ years)


Finalise on-going discussion related to type I error in two-stage design bioequivalence studies. The final output will most likely form a Q&A (to be confirmed).

Sources: Work plan for the Pharmacokinetics Working Party (PKWP) for 2018, Work plan for the Biostatistics Working Party (BSWP) for 2018.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,057 posts in 4,840 threads, 1,641 registered users;
84 visitors (0 registered, 84 guests [including 8 identified bots]).
Forum time: 16:28 CEST (Europe/Vienna)

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz